Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nɛ-carboxymethyl lysine

2010 ◽  
Vol 24 (6) ◽  
pp. 424-432 ◽  
Author(s):  
Toshihide Kawai ◽  
Izumi Takei ◽  
Mikiya Tokui ◽  
Osamu Funae ◽  
Kazunori Miyamoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Peripheral Neuropathy ◽  
Aldose Reductase ◽  
Diabetic Peripheral Neuropathy ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Carboxymethyl Lysine

scholarly journals Aldose Reductase Inhibitor, Epalrestat, Reduces Lipid Hydroperoxides in Type 2 Diabetes

2009 ◽  
Vol 56 (1) ◽  
pp. 149-156 ◽  
Author(s):  
Chie OHMURA ◽  
Hirotaka WATADA ◽  
Kosuke AZUMA ◽  
Tomoaki SHIMIZU ◽  
Akio KANAZAWA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor ◽  
Lipid Hydroperoxides

Diabetic Peripheral Neuropathy: Effect of An Aldose Reductase Inhibitor

1983 ◽  
Vol 65 (3) ◽  
pp. 19P-20P
Author(s):  
I.G. Lewin ◽  
I.A.D. O'Brien ◽  
M.H. Morgan ◽  
R.J.M. Corrall
Keyword(s):  
Peripheral Neuropathy ◽  
Aldose Reductase ◽  
Diabetic Peripheral Neuropathy ◽  
Reductase Inhibitor ◽  
Aldose Reductase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document